Overview of the global losartan market to 2026


Dublin, July 20, 2021 (GLOBE NEWSWIRE) – The “Global losartan market, by source (contract manufacturing organizations, in-house), by form (tablet, powder), by strength (25 mg, 50 mg, 100 mg, others), by distribution channel (offline, online), by Application, by End User, by Region, Forecast and Opportunity, 2026 “ report was added to ResearchAndMarkets.com offer.

The global losartan market was valued at $ 4.73 billion in 2020 and is expected to grow at a formidable rate of 7.81% during the forecast period. The global losartan market is driven by the increasing prevalence of hypertension, stroke, and diabetic nephropathy across the globe. Losartan is a medicine used to treat high blood pressure. In addition, losartan is widely used to slow long-term kidney damage due to type II diabetes, which is further expected to propel the market growth until 2026. The sudden outbreak and spread of the COVID pandemic -19 resulted in the loss of jobs for many people due to which the level of anxiety and hypertension increased among the people. This in turn increased the demand for losartan thus fueling the market growth during the forecast period. Many large biotech and pharmaceutical companies are working to manufacture losartan tablets in-house which is expected to create lucrative opportunities for market growth over the next few years.

The global losartan market is segmented on the basis of source, shape, strength, distribution channel, application, end user, company, and region. Based on the source, the market can be divided into contract and in-house manufacturing organizations. Of these, the internal segment is expected to experience the fastest growth due to the increased preference for in-house manufacturing by the major market players, as the company can have full control over the quality and quantity of the products. . On the basis of form, the market can be fragmented into tablet and powder. Here, the tablet segment dominates the market with almost 87% market share and is also expected to maintain its position over the forecast years. On the basis of the distribution channel, the market can be segmented online and offline. The offline channel is expected to dominate the market due to the growing consumer preference for purchasing drugs from a pharmacy or drugstore. The online segment is also expected to register significant growth over the next few years.

Regionally, the global Losartan market has been segmented into Asia Pacific, North America, South America, Europe, Middle East and Africa. Among these regions, North America is expected to dominate the overall losartan market due to the well-established healthcare infrastructure and the presence of large pharmaceutical and biotech giants in the region. However, Asia-Pacific is expected to experience robust market growth due to the presence of large numbers of patients with various life-threatening conditions in economies such as China and India.

The major players operating in the global losartan market are Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis International AG, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Ltd. , Torrent Pharmaceutical Ltd., Lupine Ltd., Mylan NV, Ipca Laboratories Limited, Macleods Pharmaceuticals Limited, Abbott Laboratories, Cadila Healthcare Limited and others. Companies develop advanced technologies and launch new products in order to remain competitive in the market. Other competitive strategies include mergers and acquisitions.

Goal of the study:

  • To analyze the historical growth in the size of the global Losartan market from 2016 to 2020.

  • Estimate and forecast the global Losartan market size from 2021 to 2026 and the growth rate to 2026.

  • To classify and forecast the Global Losartan Market on the basis of source, shape, strength, distribution channel, application, end-user, company, and regional distribution.

  • To identify the dominant region or segment of the global Losartan market.

  • Identify the drivers and challenges of the global losartan market.

  • To examine competitive developments such as extensions, new product launches, mergers and acquisitions, etc., in the Global Losartan Market.

  • Identify and analyze the profile of key players operating in the global Losartan market.

  • To identify the key sustainable strategies adopted by market players in the global Losartan Market.

Main topics covered:

1. Product overview

2. Research methodology

3. Impact of COVID-19 on the global losartan market

4. Executive summary

5. Voice of the customer

6. Global Losartan Market Outlook
6.1. Market size and forecast
6.1.1. By value and volume
6.2. Market share and forecasts
6.2.1. By source (contract manufacturing organizations, in-house)
6.2.2. By form (tablet, powder)
6.2.3. By force (25 mg, 50 mg, 100 mg, others)
6.2.4. By distribution channel (offline, online)
6.2.5. By application (hypertension, stroke, diabetic nephropathy, others)
6.2.6. By end user (adult, pediatric)
6.2.7. By company (2020)
6.2.8. By region
6.3. Product market map

7. North America Losartan Market Outlook

8. Outlook for the losartan market in Europe

9. Asia-Pacific Losartan Market Outlook

10. South America Losartan Market Outlook

11. Outlook for the losartan market in the Middle East and Africa

12. Market dynamics
12.1. Conductors
12.2. Challenges

13. Market trends and developments

14. Competitive landscape
14.1. Merck & Co. Inc.
14.2. Pfizer Inc.
14.3. Teva Pharmaceutical Industries Ltd.
14.4. Sanofi SA
14.5. Novartis International SA
14.6. Dr Reddy’s Laboratories Ltd.
14.7. Sun Pharmaceuticals Industries Ltd.
14.8. Aurobindo Pharma Ltée.
14.9. Torrent Pharmaceutical Ltd.
14.10. Lupine Ltd.
14.11. Mylan NV
14.12. Ipca Laboratories Limited
14.13. Macleods Pharmaceuticals Limited
14.14. Abbott Laboratories
14.15. Cadila Health Limited

15. Strategic recommendations

16. About the publisher and disclaimer

For more information on this report, visit https://www.researchandmarkets.com/r/q0fyx6

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Leave A Reply